KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Long-Term Debt Repayments (2017 - 2024)

Pacific Biosciences Of California has reported Long-Term Debt Repayments over the past 5 years, most recently at $152000.0 for Q2 2024.

  • For Q2 2024, Long-Term Debt Repayments fell 67.31% year-over-year to $152000.0; the TTM value through Mar 2025 reached $152000.0, down 91.23%, while the annual FY2024 figure was $490000.0, 73.4% down from the prior year.
  • Long-Term Debt Repayments for Q2 2024 was $152000.0 at Pacific Biosciences Of California, down from $338000.0 in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $16.0 million in Q1 2020 and troughed at $152000.0 in Q2 2024.
  • A 4-year average of $1.8 million and a median of $428000.0 in 2022 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: grew 18.54% in 2023 and later plummeted 67.31% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $16.0 million in 2020, then tumbled by 97.32% to $428000.0 in 2022, then increased by 3.97% to $445000.0 in 2023, then plummeted by 65.84% to $152000.0 in 2024.
  • Business Quant data shows Long-Term Debt Repayments for PACB at $152000.0 in Q2 2024, $338000.0 in Q1 2024, and $445000.0 in Q4 2023.